Chronic lymphocytic leukemia and regulatory B cells share IL-10 competence and immunosuppressive function

Leukemia

Volumn 27, Issue 1, 2013, Pages 170-182

  Dilillo, D J ^a   Weinberg, J B ^b   Yoshizaki, A ^a   Horikawa, M ^a   Bryant, J M ^a   Iwata, Y ^a   Matsushita, T ^a   Matta, K M ^b   Chen, Y ^b   Venturi, G M ^a   Russo, G ^c   Gockerman, J P ^a   Moore, J O ^a   Diehl, L F ^a   Volkheimer, A D ^b   Friedman, D R ^a   Lanasa, M C ^a   Hall, R P ^b   Tedder, T F ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c LABORATORIO DI PATOLOGIA VASCOLARE   (Italy)

Author keywords

B10 cells; CLL; IL 10; immunosuppression; regulatory B cell

Indexed keywords

CD38 ANTIGEN; INTERLEUKIN 10; LIPOPOLYSACCHARIDE; PROTEIN KINASE ZAP 70;

ADULT; AGED; ANIMAL EXPERIMENT; ANTIGEN EXPRESSION; ARTICLE; B LYMPHOCYTE; CHRONIC LYMPHATIC LEUKEMIA; CONTROLLED STUDY; CYTOGENETICS; CYTOKINE RELEASE; FEMALE; HUMAN; HUMAN CELL; IMMUNOCOMPETENT CELL; IMMUNOFLUORESCENCE; IMMUNOGLOBULIN VARIABLE REGION; IMMUNOMODULATION; LEUKEMIA CELL; MAJOR CLINICAL STUDY; MALE; MOUSE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; TRANSGENIC MOUSE;

ANIMALS; B-LYMPHOCYTES; B-LYMPHOCYTES, REGULATORY; CELLS, CULTURED; FLUORESCENT ANTIBODY TECHNIQUE; HUMANS; IMMUNOSUPPRESSION; INTERLEUKIN-10; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; LIPOPOLYSACCHARIDES; MICE; MICE, TRANSGENIC; PROTO-ONCOGENE PROTEINS;

EID: 84873567628     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2012.165     Document Type: Article

References (51)

1. Chiorazzi N, Rai KR, Ferrarini M. Chronic lymphocytic leukemia. N Engl J Med 2005; 352: 804-815.
2. Damle RN, Ghiotto F, Valetto A, Albesiano E, Fais F, Yan XJ et al. B-cell chronic lymphocytic leukemia cells express a surface membrane phenotype of activated, antigen-experienced B lymphocytes. Blood 2002; 99: 4087-4093.
3. Nordgren TM, Joshi SS. The etiology of chronic lymphocytic leukemia: another look at the relationship between B1 cells and CLL. Open Leuk J 2010; 3: 69-73.
4. Chiorazzi N, Ferrarini M. Cellular origin(s) of chronic lymphocytic leukemia: cautionary notes and additional considerations and possibilities. Blood 2011; 117: 1781-1791.
5. Gorgun G, Holderried TA, Zahrieh D, Neuberg D, Gribben JG. Chronic lymphocytic leukemia cells induce changes in gene expression of CD4 and CD8 T cells. J Clin Invest 2005; 115: 1797-1805.
6. Bichi R, Shinton SA, Martin ES, Koval A, Calin GA, Cesari R et al. Human chronic lymphocytic leukemia modeled in mouse by targeted TCL1 expression. Proc Natl Acad Sci USA 2002; 99: 6955-6960.
7. Hamblin TJ. The TCL1 mouse as a model for chronic lymphocytic leukemia. Leuk Res 2010; 34: 135-136.
8. Efanov A, Zanesi N, Nazaryan N, Santanam U, Palamarchuk A, Croce CM et al. CD5\+CD23\+ leukemic cell populations in TCL1 transgenic mice show significantly increased proliferation and Akt phosphorylation. Leukemia 2010; 24: 970-975.
9. Johnson AJ, Lucas DM, Muthusamy N, Smith LL, Edwards RB, De Lay MD et al. Characterization of the TCL-1 transgenic mouse as a preclinical drug development tool for human chronic lymphocytic leukemia. Blood 2006; 108: 1334-1338.
10. Yan XJ, Albesiano E, Zanesi N, Yancopoulos S, Sawyer A, Romano E et al. B cell receptors in TCL1 transgenic mice resemble those of aggressive, treatmentresistant human chronic lymphocytic leukemia. Proc Natl Acad Sci USA 2006; 103: 11713-11718.
11. Enzler T, Kater AP, Zhang W, Widhopf II GF, Chuang HY, Lee J et al. Chronic lymphocytic leukemia of Em-TCL1 transgenic mice undergoes rapid cell turnover that can be offset by extrinsic CD257 to accelerate disease progression. Blood 2009; 114: 4469-4476.
12. Gorgun G, Ramsay AG, Holderried TA, Zahrieh D, Le Dieu R, Liu F et al. Em-TCL1 mice represent a model for immunotherapeutic reversal of chronic lymphocytic leukemia-induced T-cell dysfunction. Proc Natl Acad Sci USA 2009; 106: 6250-6255.
13. Herling M, Patel KA, Khalili J, Schlette E, Kobayashi R, Medeiros LJ et al. TCL1 shows a regulated expression pattern in chronic lymphocytic leukemia that correlates with molecular subtypes and proliferative state. Leukemia 2006; 20: 280-285.
14. Browning RL, Geyer SM, Johnson AJ, Jelinek DF, Tschumper RC, Call TG et al. Expression of TCL-1 as a potential prognostic factor for treatment outcome in B-cell chronic lymphocytic leukemia. Leuk Res 2007; 31: 1737-1740.
15. Iwata Y, Matsushita T, Horikawa M, DiLillo DJ, Yanaba K, Venturi GM et al. Characterization of a rare IL-10-competent B cell subset in humans that parallels mouse regulatory B10 cells. Blood 2011; 117: 530-541.
16. Yanaba K, Bouaziz J-D, Haas KM, Poe JC, Fujimoto M, Tedder TF. A regulatory B cell subset with a unique CD1dhiCD5\+ phenotype controls T cell-dependent inflammatory responses. Immunity 2008; 28: 639-650.
17. Matsushita T, Yanaba K, Bouaziz J-D, Fujimoto M, Tedder TF. Regulatory B cells inhibit EAE initiation in mice while other B cells promote disease progression. J Clin Invest 2008; 118: 3420-3430.
18. DiLillo DJ, Matsushita T, Tedder TF. B10 cells and regulatory B cells balance immune responses during inflammation, autoimmunity, and cancer. Ann NY Acad Sci 2010; 1183: 38-57.
19. Ray A, Basu S, Williams CB, Salzman NH, Dittel BN. A novel IL-10-independent regulatory role for B cells in suppressing autoimmunity by maintenance of regulatory T cells via GITR ligand. J Immunol 2012; 188: 3188-3198.
20. Yanaba K, Bouaziz J-D, Matsushita T, Tsubata T, Tedder TF. The development and function of regulatory B cells expressing IL-10 (B10 cells) requires antigen receptor diversity and TLR signals. J Immunol 2009; 182: 7459-7472.
21. Haas KM, Watanabe R, Matsushita T, Nakashima H, Ishiura N, Okochi H et al. Protective and pathogenic roles for B cells during systemic autoimmunity in NZB/W F1 mice. J Immunol 2010; 184: 4789-4800.
22. Spencer NF, Daynes RA. IL-12 directly stimulates expression of IL-10 by CD5\+ B cells and IL-6 by both CD5\+ and CD5 B cells: possible involvement in ageassociated cytokine dysregulation. Int Immunol 1997; 9: 745-754.
23. Brummel R, Lenert P. Activation of marginal zone B cells from lupus mice with type A(D) CpG-oligodeoxynucleotides. J Immunol 2005; 174: 2429-2434.
24. Evans JG, Chavez-Rueda KA, Eddaoudi A, Meyer-Bahlburg A, Rawlings DJ, Ehrenstein MR et al. Novel suppressive function of transitional 2 B cells in experimental arthritis. J Immunol 2007; 178: 7868-7878.
25. Bouaziz J-D, Yanaba K, Tedder TF. Regulatory B cells as inhibitors of immune responses and inflammation. Immunol Rev 2008; 224: 201-214.
26. Matsushita T, Horikawa M, Iwata Y, Tedder TF. Regulatory B cells (B10 cells) and regulatory T cells have independent roles in controlling EAE initiation and latephase immunopathogenesis. J Immunol 2010; 185: 2240-2252.
27. Horikawa M, Minard-Colin V, Matsushita T, Tedder TF. Regulatory B cell production of IL-10 inhibits lymphoma depletion during CD20 immunotherapy in mice. J Clin Invest 2011; 121: 4268-4280.
28. Hallek M, Cheson BD, Catovsky D, Caligaris-Cappio F, Dighiero G, Dohner H et al. Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines. Blood 2008; 111: 5446-5456.
29. Volkheimer AD, Weinberg JB, Beasley BE, Whitesides JF, Gockerman JP, Moore JO et al. Progressive immunoglobulin gene mutations in chronic lymphocytic leukemia: evidence for antigen-driven intraclonal diversification. Blood 2007; 109: 1559-1567.
30. Kang SM, Narducci MG, Lazzeri C, Mongiovi AM, Caprini E, Bresin A et al. Impaired T-and B-cell development in Tcl1-deficient mice. Blood 2005; 105: 1288-1294.
31. Zhou L-J, Smith HM, Waldschmidt TJ, Schwarting R, Daley J, Tedder TF. Tissuespecific expression of the human CD19 gene in transgenic mice inhibits antigenindependent B lymphocyte development. Mol Cell Biol 1994; 14: 3884-3894.
32. Matsushita T, Tedder TF. Identifying regulatory B cells (B10 cells) that produce IL-10. Methods Mol Biol 2011; 677: 99-111.
33. Uchida J, Lee Y, Hasegawa M, Liang Y, Bradney A, Oliver JA et al. Mouse CD20 expression and function. Int Immunol 2004; 16: 119-129.
34. Haas KM, Sen S, Sanford IG, Miller AS, Poe JC, Tedder TF. CD22 ligand binding regulates normal and malignant B lymphocyte survival in vivo. J Immunol 2006; 177: 3063-3073.
35. Romero-Calvo I, Ocon B, Martinez-Moya P, Suarez MD, Zarzuelo A, Martinez-Augustin O et al. Reversible Ponceau staining as a loading control alternative to actin in Western blots. Anal Biochem 2010; 401: 318-320.
36. Kitabayashi A, Hirokawa M, Miura AB. The role of interleukin-10 (IL-10) in chronic B-lymphocytic leukemia: IL-10 prevents leukemic cells from apoptotic cell death. Int J Hematol 1995; 62: 99-106.
37. Fayad L, Keating MJ, Reuben JM, O0Brien S, Lee BN, Lerner S et al. Interleukin-6 and interleukin-10 levels in chronic lymphocytic leukemia: correlation with phenotypic characteristics and outcome. Blood 2001; 97: 256-263.
38. Knauf WU, Ehlers B, Bisson S, Thiel E. Serum levels of interleukin-10 in B-cell chronic lymphocytic leukemia. Blood 1995; 86: 4382-4383.
39. Ramachandra S, Metcalf RA, Fredrickson T, Marti GE, Raveche E. Requirement for increased IL-10 in the development of B-1 lymphoproliferative disease in a murine model of CLL. J Clin Invest 1996; 98: 1788-1793.
40. Minard-Colin V, Xiu Y, Poe JC, Horikawa M, Hamaguchi Y, Haas KM et al. Lymphoma depletion during CD20 immunotherapy in mice is mediated by macrophage FcgRI, FcgRIII, and FcgRIV. Blood 2008; 112: 1205-1213.
41. Moore KW, de Waal Malefyt R, Coffman RL, O0Garra A. Interleukin-10 and the interleukin-10 receptor. Annu Rev Immunol 2001; 19: 683-765.
42. de Waal Malefyt R, Haanen J, Spits H, Roncarolo MG, te Velde A, Figdor C et al. Interleukin 10 (IL-10) and viral IL-10 strongly reduce antigen-specific human T cell proliferation by diminishing the antigen-presenting capacity of monocytes via downregulation of class II major histocompatibility complex expression. J Exp Med 1991; 174: 915-924.
43. Matutes E, Wechsler A, Gomez R, Cherchi M, Catovsky D. Unusual T-cell phenotype in advanced B-chronic lymphocytic leukaemia. Br J Haematol 1981; 49: 635-642.
44. Chiorazzi N, Fu SM, Montazeri G, Kunkel HG, Rai K, Gee T. T cell helper defect in patients with chronic lymphocytic leukemia. J Immunol 1979; 122: 1087-1090.
45. Lauria F, Foa R, Mantovani V, Fierro MT, Catovsky D, Tura S. T-cell functional abnormality in B-chronic lymphocytic leukaemia: evidence of a defect of the T-helper subset. Br J Haematol 1983; 54: 277-283.
46. Beyer M, Kochanek M, Darabi K, Popov A, Jensen M, Endl E et al. Reduced frequencies and suppressive function of CD4\+CD25hi regulatory T cells in patients with chronic lymphocytic leukemia after therapy with fludarabine. Blood 2005; 106: 2018-2025.
47. Motta M, Rassenti L, Shelvin BJ, Lerner S, Kipps TJ, Keating MJ et al. Increased expression of CD152 (CTLA-4) by normal T lymphocytes in untreated patients with B-cell chronic lymphocytic leukemia. Leukemia 2005; 19: 1788-1793.
48. Pekarsky Y, Zanesi N, Aqeilan RI, Croce CM. Animal models for chronic lymphocytic leukemia. J Cell Biochem 2007; 100: 1109-1118.
49. Klein U, Tu Y, Stolovitzky GA, Mattioli M, Cattoretti G, Husson H et al. Gene expression profiling of B cell chronic lymphocytic leukemia reveals a homogeneous phenotype related to memory B cells. J Exp Med 2001; 194: 1625-1638.
50. Hodgson K, Ferrer G, Montserrat E, Moreno C. Chronic lymphocytic leukemia and autoimmunity: a systematic review. Haematologica 2011; 96: 752-761.
51. Maseda D, Smith SH, DiLillo DJ, Bryant JM, Candando KM, Weaver CT et al. Regulatory B10 cells differentiate into antibody-secreting cells after transient IL-10 production in vivo. J Immunol 2012; 188: 1036-1048.